Skip to main content
Upstream Bio, Inc. logo

Upstream Bio, Inc. — Investor Relations & Filings

Ticker · UPB ISIN · US91678A1079 US Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2026-06-10 Declaration of Voting R…
Country US United States of America
Listing US UPB

About Upstream Bio, Inc.

https://upstreambio.com/

Upstream Bio, Inc. is a clinical-stage biotechnology company that develops treatments for inflammatory diseases, with a primary focus on severe respiratory disorders. The company's lead product candidate is verekitug, a monoclonal antibody designed to target and inhibit the thymic stromal lymphopoietin (TSLP) receptor, an upstream driver of pro-inflammatory signaling. Verekitug is in clinical development for the treatment of conditions including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an SEC Form 8-K current report, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides detailed vote counts for proposals at the company’s 2026 Annual Meeting (election of directors and ratification of auditors). This matches the definition for “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-06-10 English
10-Q - Upstream Bio, Inc. (0002022626) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Upstream Bio, Inc. (0002022626) (Filer)
Earnings Release Classification · 85% confidence The document is a Form 8-K current report under Item 2.02 announcing and furnishing the company’s quarterly results press release for the period ended March 31, 2026. It serves as the initial announcement of period financial results rather than containing full financial statements or transcripts. This matches the “Earnings Release” category. Q1 2026
2026-05-13 English
8-K - Upstream Bio, Inc. (0002022626) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 26, 2026. It announces the company's financial results and business highlights for the quarter and year ended December 31, 2025, and includes a press release as an exhibit. The text explicitly states that the information is being furnished and is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is an initial announcement of financial results rather than a full detailed report. The document length is 3531 characters, which is relatively short and consistent with a press release or earnings announcement rather than a comprehensive report. Therefore, this filing corresponds to an Earnings Release (ER).
2026-03-26 English
4 - Upstream Bio, Inc. (0002022626) (Issuer)
Director's Dealing
2026-03-17 English
4 - Upstream Bio, Inc. (0002022626) (Issuer)
Director's Dealing
2026-03-17 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.